COSMO Pharmaceuticals SA - Asset Resilience Ratio

Latest as of June 2026: 23.63%

COSMO Pharmaceuticals SA (0RGI) has an Asset Resilience Ratio of 23.63% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See COSMO Pharmaceuticals SA working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

£164.41 Million
≈ $220.79 Million USD Cash + Short-term Investments

Total Assets

£695.64 Million
≈ $934.18 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2009–2025)

This chart shows how COSMO Pharmaceuticals SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of COSMO Pharmaceuticals SA.

Liquid Assets Composition Over Time

This chart breaks down COSMO Pharmaceuticals SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 0RGI total debt and obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents £0.00 0%
Short-term Investments £164.41 Million 23.63%
Total Liquid Assets £164.41 Million 23.63%

Asset Resilience Insights

  • Good Liquidity Position: COSMO Pharmaceuticals SA maintains a healthy 23.63% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

COSMO Pharmaceuticals SA Industry Peers by Asset Resilience Ratio

Compare COSMO Pharmaceuticals SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
No industry peers found with asset resilience data.

Annual Asset Resilience Ratio for COSMO Pharmaceuticals SA (2009–2025)

The table below shows the annual Asset Resilience Ratio data for COSMO Pharmaceuticals SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 10.92% £66.84 Million
≈ $89.76 Million
£612.16 Million
≈ $822.07 Million
+8.14pp
2024-12-31 2.78% £17.99 Million
≈ $24.16 Million
£646.77 Million
≈ $868.56 Million
-4.16pp
2022-12-31 6.94% £52.70 Million
≈ $70.77 Million
£759.59 Million
≈ $1.02 Billion
+4.00pp
2021-12-31 2.94% £23.65 Million
≈ $31.76 Million
£805.56 Million
≈ $1.08 Billion
-1.58pp
2020-12-31 4.51% £26.91 Million
≈ $36.14 Million
£596.16 Million
≈ $800.59 Million
-22.46pp
2019-12-31 26.97% £157.82 Million
≈ $211.94 Million
£585.16 Million
≈ $785.82 Million
+25.04pp
2018-12-31 1.93% £12.05 Million
≈ $16.19 Million
£625.69 Million
≈ $840.24 Million
-3.65pp
2017-12-31 5.57% £27.76 Million
≈ $37.28 Million
£497.97 Million
≈ $668.73 Million
-5.44pp
2016-12-31 11.01% £48.84 Million
≈ $65.58 Million
£443.47 Million
≈ $595.55 Million
+0.72pp
2015-12-31 10.29% £45.06 Million
≈ $60.52 Million
£437.94 Million
≈ $588.12 Million
-0.94pp
2014-12-31 11.23% £25.33 Million
≈ $34.01 Million
£225.62 Million
≈ $302.99 Million
-38.91pp
2013-12-31 50.13% £121.82 Million
≈ $163.60 Million
£243.00 Million
≈ $326.33 Million
+50.13pp
2012-12-31 0.00% £1.00
≈ $1.34
£183.30 Million
≈ $246.15 Million
-0.11pp
2010-12-31 0.11% £101.00K
≈ $135.63K
£91.83 Million
≈ $123.31 Million
-0.08pp
2009-12-31 0.19% £139.00K
≈ $186.66K
£71.46 Million
≈ $95.97 Million
--
pp = percentage points

About COSMO Pharmaceuticals SA

LSE:0RGI UK
Market Cap
$1.12 Billion
£835.62 Million GBP
Market Cap Rank
#8410 Global
#28 in UK
Share Price
£55.70
Change (1 day)
-2.96%
52-Week Range
£52.20 - £125.25
All Time High
£173.85
About

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more